CannTrust is getting ready to launch a clinical trial to assess the effectiveness of its cannabidiol (CBD) oil capsules on slowing the progression of amyotrophic lateral sclerosis (ALS) and other motor neuron diseases (MNDs). This new study is the result of a collaboration between Canada-based CannTrust and Gold Coast University Hospital, one of the leading tertiary […]

<!– Market News –> July 15, 2018 – By Joseph Taylor Oz Management Lp decreased Insys Therapeutics Inc New (Put) (INSY) stake by 66.22% reported in 2018Q1 SEC filing. Oz Management Lp sold 58,800 shares as Insys Therapeutics Inc New (Put) (INSY)’s stock declined 15.10%. The Oz Management Lp holds 30,000 shares with $181,000 value, […]

<!– Market News –> July 15, 2018 – By Joe Cepeda Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) had an increase of 29.94% in short interest. NVIV’s SI was 315,100 shares in July as released by FINRA. Its up 29.94% from 242,500 shares previously. With 329,200 avg volume, 1 days are for Invivo Therapeutics Holdings Corp (NASDAQ:NVIV)’s […]

Welcome back to Higher Law, our weekly briefing on all things cannabis. I’m Cheryl Miller, reporting for Law.com from Sacramento. Hope your Fourth of July was a blast. This week, we’re looking at Cleveland’s interest in a recreational marijuana market, even though it may be years away. Plus, Eaze Solutions, represented by Boies Schiller Flexner, […]

Zogenix, Inc. (ZGNX – Free Report) announced successful completion of its second confirmatory phase III study (Study 1504) evaluating its pipeline candidate, ZX008 (low-dose fenfluramine hydrochloride), for treating Dravet syndrome, a type of epilepsy in children and young adults. The data was consistent with the positive results observed in the first pivotal phase III study in […]

The study is designed to evaluate the efficacy of CannTrust’s Cannabidiol Oil Capsules in slowing Amyotrophic Lateral Sclerosis (ALS) progression VAUGHAN, ON, July 11, 2018 /PRNewswire/ – CannTrust Holdings Inc. (“CannTrust” or the “Company”, TSX: TRST), one of Canada’s leading licensed producers of medical cannabis, announced today that it has partnered with Australia’s Gold Coast […]

Zynerba Pharmaceuticals has launched a pivotal Phase 3 clinical trial, called CONNECT-FX, that will assess the safety and effectiveness of its cannabis-based ZYN002 as a potential therapy to treat behavioral symptoms in patients with fragile X syndrome. Top-line results from the trial are expected in the second half of 2019. ZYN002 is administered as a gel through […]

Zogenix, based in Emeryville, California, announced positive top-line data from its second confirmatory Phase III clinical trial of ZX008 (low-dose fenfluramine hydrochloride) for children and young adults with Dravet syndrome. Dravet syndrome is a rare form of epilepsy. The results from this second trial were consistent with the first, which hit the primary endpoint and […]

The six-month study will be led by Gold Coast Neurologist, Dr. Arman Sabet, MD. Gold Coast is one of Australia’s leading tertiary referral institutions for ALS management and Dr. Sabet has been involved in many international clinical trials specializing in neuromuscular disorders and stroke. Dr. Sabet’s research will also analyze the effects of CannTrust CBD […]

CannTrust Holdings announced its involvement in a six-month clinical trial to determine the effectiveness of CBD oil capsules treating ALS or Motor Neuron Disease. CannTrust Holdings (TSX:TRST) announced its involvement in a six-month clinical trial to determine the effectiveness of cannabidiol (CBD) oil capsules treating Amyotrophic Lateral Sclerosis (ALS) or Motor Neuron Disease (MND). As quoted […]